2022
RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice.
Joshi AA, Wu Y, Deng S, Preston-Hurlburt P, Forbes JM, Herold KC. RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice. Clinical Immunology 2022, 245: 109165. PMID: 36257528, DOI: 10.1016/j.clim.2022.109165.Peer-Reviewed Original ResearchConceptsXenograft rejectionIL-17AHumanized miceIL-1βT cellsImmune responseRAGE antagonistsAdaptive human immune responsesPD-1 expressionSkin graft rejectionHuman immune cell responsesImmune cell responsesHuman immune responseHuman immune cellsInnate immune responseAdvanced glycation endproductsInhibition of pathwaysSmall molecule antagonistsMultiple inflammatory processesAZ therapyRAGE antagonismGraft rejectionIL-23Serum levelsMedian time
2012
RAGE Expression in Human T Cells: A Link between Environmental Factors and Adaptive Immune Responses
Akirav EM, Preston-Hurlburt P, Garyu J, Henegariu O, Clynes R, Schmidt AM, Herold KC. RAGE Expression in Human T Cells: A Link between Environmental Factors and Adaptive Immune Responses. PLOS ONE 2012, 7: e34698. PMID: 22509345, PMCID: PMC3324532, DOI: 10.1371/journal.pone.0034698.Peer-Reviewed Original ResearchConceptsHuman immune responseT cellsImmune responseHuman T cellsRAGE expressionAntigen-specific T cellsAdaptive human immune responsesAdaptive immune cellsSpecific T cellsHealthy control subjectsAdaptive immune responsesExpression of RAGELevels of RAGEInnate immune responseAdvanced glycation endproductsActivated T cellsT cell activationIL-17AGlucose controlControl subjectsIL-5Immune cellsGlycation endproductsCell activationPatients